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Laryngeal dysplasia is a common clinical concern. Despite major advancements, a significant number of patients with this condition
progress to invasive squamous cell carcinoma. Osteopontin (OPN) is a secreted glycoprotein, whose expression is markedly elevated
in several types of cancers. We explored OPN as a candidate biomarker for laryngeal dysplasia. To this aim, we examined OPN
expression in 82 cases of dysplasia and in hyperplastic and normal tissue samples. OPN expression was elevated in all severe dysplasia
samples, but not hyperplastic samples, with respect to matched normal mucosa. OPN expression levels correlated positively with
degree of dysplasia (P¼0.0094) and negatively with disease-free survival (Po0.0001). OPN expression was paralleled by cell surface
reactivity for CD44v6, an OPN functional receptor. CD44v6 expression correlated negatively with disease-free survival, as well
(P¼0.0007). Taken as a whole, our finding identify OPN and CD44v6 as predictive markers of recurrence or aggressiveness in
laryngeal intraepithelial neoplasia, and overall, point out an important signalling complex in the evolution of laryngeal dysplasia.
British Journal of Cancer (2007) 97, 1545–1551. doi:10.1038/sj.bjc.6604070 www.bjcancer.com
Published online 6 November 2007
& 2007 Cancer Research UK
Keywords: OPN; SCC; dysplasia; marker
                                              
Laryngeal squamous cell carcinoma (LSCC) is the most common
type of head and neck squamous cell carcinoma (HNSCC). LSCC
accounts for 1–2% of all malignancies diagnosed worldwide
(Vokes et al, 1993; Licitra et al, 2003; Mao et al, 2004).
Notwithstanding primary prevention, screening, surgical treat-
ment, and radiotherapy, the long-term survival rate of LSCC
patients has remained substantially unchanged in the last two
decades (Hoffman et al, 1998). Survival of the patients depends on
the stage of the disease; therefore, early detection and timely
therapy are essential (Vokes et al, 1993; Hoffman et al, 1998;
Licitra et al, 2003; Mao et al, 2004).
Laryngeal squamous cell carcinoma usually develops in a
multistep process: normal mucosa – dysplasia (laryngeal intra-
epithelial neoplasia, LIN) – LSCC in situ – invasive LSCC (Rosai
et al, 1992; Tabor et al, 2002; Zuckerberg, 2002; Johnson, 2003).
Dysplasia is characterised by increased cell growth, cellular atypia
(nuclear and nucleolar abnormalities, altered nuclear/cyto-
plasmatic ratio, and altered cytoplasmatic differentiation), and
architectural alteration of the epithelium. Conventionally, the
dysplastic changes are graded as mild (LIN I: dysplasia limited to
the basal third of the epithelium, few mitoses), moderate (LIN II:
dysplasia involving the lower two-thirds of the epithelium, marked
nuclear changes, prominent nucleoli, mitoses in the parabasal, and
intermediate layers), and severe (LIN III: dysplasia involving more
than two-thirds of the epithelial thickness, nuclear pleomorphism
and hyperchromasia, prominent nucleoli, cell crowding, and
atypical mitoses). Often, severe dysplasia and in situ carcinoma
are grouped in the same category (Rosai et al, 1992; Tabor et al,
2002; Zuckerberg, 2002; Johnson, 2003). Early forms of dysplasia
may be reversible if the initial stimuli (like smoke and volatile
irritating substances) are removed, while severe dysplasia, if left
untreated, is regarded as a precancerous lesion (Rosai et al, 1992;
Tabor et al, 2002; Zuckerberg, 2002; Johnson, 2003). For patients
with mild or moderate dysplasia, the reported rate of progression
to invasive cancer is up to 11.5 and 45%, respectively. In severe
dysplasia, higher rates of progression are commonly reported
(Rosai et al, 1992; Tabor et al, 2002; Zuckerberg, 2002; Johnson,
2003). The molecular events that induce the evolution of dysplasia
to carcinoma are still unknown (Cowan et al, 1992; Zuckerberg,
2002; Perez-Ordonez et al, 2006).
Osteopontin (OPN), also known as SPP1 (secreted phospho-
protein 1), is a highly acidic calcium-binding glycosylated
phosphoprotein (Weber, 2001; Rittling and Chambers, 2004;
Rangaswami et al, 2006). OPN can function both as cell adhesion
molecule and as cytokine. It binds to the cell surface receptors av-
or b1-containing integrins and CD44v6 (Weber, 2001; Rittling and
Chambers, 2004; Rangaswami et al, 2006), thereby supporting
proliferation, chemotaxis, attachment, and migration of many cell
types. CD44 is a cell surface glycoprotein that is involved in
regulating cell–cell and cell–matrix interactions, migration, and
tumour growth and progression (Ponta et al, 2003). CD44 is
Received 18 July 2007; revised 1 October 2007; accepted 9 October
2007; published online 6 November 2007
*Correspondence: Dr A Celetti; E-mail: celetti@unina.it
British Journal of Cancer (2007) 97, 1545–1551
& 2007 Cancer Research UK All rights reserved 0007– 0920/07 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sexpressed as a standard receptor (CD44s) and in multiple splice
isoforms (CD44v), whose expression is altered during tumour
growth and progression. Expression of the ‘v6’ variant exon of
CD44 is necessary for OPN binding (Ponta et al, 2003). OPN is
overexpressed in many human tumours, for example, colon,
breast, liver, prostate, gastric, ovarian, lung, thyroid, and kidney
carcinomas (Agrawal et al, 2002; Kang et al, 2003; Ye et al, 2003;
Schorge et al, 2004; Donati et al, 2005; Guarino et al, 2005;
Matusan et al, 2006).
We recently reported that OPN and CD44v6 are overexpressed
in full-blown LSCC (Celetti et al, 2005). Here, we have investigated
the role of the OPN/CD44v6 axis in laryngeal dysplasia.
MATERIALS AND METHODS
Study population
Patients (82 cases: 77 men and 5 women) underwent surgery at the
Otolaryngology Department of the University Federico II of Naples
between January 1993 and December 2001. The patients’ age
ranged from 23 to 83 years, with a mean of 62.46 years. Paraffin
blocks were retrieved from the files of the Department of
Biomorphological and Functional Sciences, Pathology Section,
University Federico II of Naples. Each patient agreed to and signed
a consent for the treatment of clinical data and tissues for
diagnostic and research purposes, according to the guidelines of
the Institutional Ethic Committee. For all the patients, clinico-
pathologic and follow-up data were recorded (Table 1). Before
surgery, patients underwent otolaryngological, fibreoptic, and
radiological evaluation. The mean follow-up time was 10.1 years
(range: 8–13 years). Follow-up consisted in clinical and radi-
ological evaluation at 3-month intervals for the first year and
6-months intervals thereafter. At completion of follow-up, patients
were subdivided into alive with absence of relapse (no); alive with
evidence of recurrent disease (LIN); and alive with progression of
disease to LSCC (SCC).
After surgical resection, tissues were fixed in 10% neutral
buffered formalin and embedded in paraffin blocks. Sections (4-mM
thick) were stained with haematoxylin–eosin for histological
examination. The pathologic analysis was performed in a blinded
fashion to the clinical informations. The cytological evaluation was
according to standard criteria (Evans et al, 1986; Gale et al, 2000;
Tabor et al, 2003).
Immunohistochemistry
Four-micromolar thick serial sections, mounted on poly-L-lysine-
coated glass slides, were dewaxed, rehydrated through multiple
graded ethanol solutions, treated with 3% hydrogen peroxide for
5min to inactivate endogenous peroxidases, and washed in
distilled water. After antigen retrieval (microwave oven 5min 3
times, in 1% citrate buffer), nonspecific binding was blocked by
incubation (2h at room temperature) with 1.5% blocking serum.
Slides were first incubated with anti-OPN (final concentration:
5mgml
 1) (10A16; Assay Designs, Ann Arbor, MI, USA) or anti-
CD44v6 (dilution of 1:100) (NCL-CD44v6, clone VFF-7; Novocas-
tra Laboratories Ltd, Newcastle upon Tyne, UK) monoclonal
antibodies and then with biotinylated anti-IgG and the premixed
avidin–biotin complex (overnight at 41C) (Vectastain ABC kits;
Vector Laboratories, Burlingame, CA, USA). The immune reaction
was revealed with 0.06mmoll
 1 diaminobenzidine (DAB-DAKO,
Carpinteria, CA, USA) and 2mmoll
 1 hydrogen peroxide. Finally,
slides were counterstained with haematoxylin and coverslipped
with a synthetic mounting media. Control slides in the presence of
preimmune serum were included for each staining as an additional
negative control. Anti-OPN antibody was preincubated with a
fivefold molar excess of OPN peptide to ascertain specificity of the
reaction.
The results of the immunohistochemical staining were evaluated
separately and in a blinded fashion by two pathologists. Five
representative microscopic areas at  400 magnification were
randomly selected for examination. Expression of OPN was
semiquantitatively assessed as percentage of positive cells with
respect to the total number of epithelial cells. The samples were
assigned to one of the four following categories: 0 (absence of
positive cells); þ (o10% of positive cells); þþ (10–50% of
positive cells); and þþþ (450% of positive cells). Staining
of CD44v6 was classified as ‘lower’ (lower third) (L), ‘lower and
middle’ (up to two-thirds of the thickness of the epithelium) (M),
and ‘full thickness’ (F).
Statistical analysis
The Pearson’s w
2 test was used to assess the statistical significance
of the frequency distribution of all categories of OPN or CD44v6
expression by degree of dysplasia or by relapse. Differences were
significant with P-value o0.05.
Nonparametric Spearman’s correlation coefficient method was
used to assess the statistical significance of the correlation between
OPN expression vs CD44v6 positivity. A test was run for all the
patients’ cohort combined or grouped by degree of dysplasia or by
type of relapse. Correlations were significant when P-value was
o0.05. Disease-free survival curves of the patients were calculated
using the Kaplan–Meier method, and analysis was performed by
the log-rank test. Differences were significant when Po0.05. In this
analysis, a group of 31 patients has been censored for lack of data.
Statistical analysis was performed using the JMP software program
(version 5.1.1; SAS Institute Inc., Austin, TX, USA).
RESULTS
Immunohistochemical detection of OPN and CD44v6 in
laryngeal dysplasia
Eighty-two laryngeal samples with different degree of dysplasia
(Table 1) and the matched normal mucosa were tested for OPN
expression by immunohistochemistry with an anti-OPN-specific
monoclonal antibody. Representative stainings are shown in
Figure 1, and the entire data set is reported in Table 2. OPN was
virtually undetectable (o2.0% of the cells) in normal tissue
(n¼10). Dysplastic areas showed different degrees of OPN
positivity. In most (76%) of mild dysplasia cases, only few cells
Table 1 Clinicopathological features of studied laryngeal intraepithelial
neoplasia (LIN) patients
Characteristics Total (%)
No. of subjects
Male 77 (94)
Female 5 (6)
Disease site
Glottis–hypoglottis 43 (53)
Supraglottis 39 (47)
Degree of dysplasia
Mild 21 (47)
Moderate 8 (19)
Severe 53 (64)
Relapse
No 35 (43)
LIN 10 (12)
SCC 37 (45)
SCC¼squamous cell carcinoma.
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s(þ) were positive (Figure 1A), while 50% of moderate and severe
dysplasia samples had intense (þþþ) OPN staining (Figures 1E
and G). Only 20% cases of mild dysplasia were highly positive for
OPN (þþþ); interestingly, in these samples, OPN expression
coexisted with a diffuse CD44v6 staining (see below) (Figures 1C
and D).
The samples were also analysed for the expression of CD44v6,
the receptor that is involved in OPN binding (Table 2). Only basal
cells (L category) were CD44v6 positive in 76% of mild dysplasia
samples (Figure 1B). Instead, in moderate dysplasia, CD44v6
positivity was found in the basal two-thirds (M category)
(Figure 1F) or even full thickness (F category) of the epithelium.
Finally, 50% of severe dysplasia samples showed a full-thickness (F
category) CD44v6 staining (Figure 1H). The association between
OPN and CD44v6 immunoreactivity resulted significant when
analysed by the Spearman’s rank correlation test (Table 3A). The
frequency distribution of OPN positivity or CD44v6 immuno-
reactivity by degree of dysplasia resulted highly significant at
Pearson’s w
2 test (Table 4A).
Foci of squamous metaplasia of laryngeal cylindric-cell-lined
areas were almost constantly present in our samples. Metaplastic
areas (n¼20) were almost constantly negative for OPN and
CD44v6 staining (Figures 2A and B). Only in few (5%) cases, we
observed an intense (þþþ) OPN staining paralleled by full-
thickness CD44v6 positivity in the squamous metaplastic cells
(Figures 2C and D). Although the ultimate statistical relevance of
this finding is still to be verified on larger series of cases, it is
interesting to note that these OPN- and CD44v6-positive
metaplasia areas were found in patients with a history of
development of SCC at the follow-up.
OPN and CD44v6 expression levels in laryngeal dysplasia
negatively correlate with disease-free survival
The disease-free survival rate in patients affected by laryngeal
dysplasia negatively correlated with intense OPN staining and full-
thickness CD44v6 positivity. As shown by the Kaplan–Meier
Mild
Moderate Severe
OPN OPN CD44v6 CD44v6
OPN OPN CD44v6 CD44v6
A B C D
E F G H
Figure 1 (A and B) A representative case of mild degree dysplasia showing weak immunostaining for OPN (A) and CD44v6 positivity restricted to the
lower third of the epithelium (B)(  150). (C and D) Another mild dysplasia sample showing stronger immunostaining for both the markers ( 150).
(E and F) A representative case of moderate dysplasia showing a strong immunostaining for OPN (E) and a CD44v6 positivity involving the lower two-
thirds of the epithelium (F)(  250). (G and H) A case of high-grade dysplasia showing strong immunostaining for OPN (G) and CD44v6 positivity up to
the upper third of the epithelium (H)(  400).
Table 2 OPN and CD44v6 positivity in laryngeal intraepithelial neoplasia
at different degree
LIN OPN positivity
a CD44v6 positivity
a
Mild (21) 16/21 (+) 16/21 (L)
1/21 (++) 2/21 (M)
4/21 (+++) 3/21 (F)
Moderate (8) 3/8 (+) 2/8 (L)
1/8 (++) 3/8 (M)
4/8 (+++) 3/8 (F)
Severe (53) 16/53 (+) 15/53 (L)
11/53 (++) 12/53 (M)
26/53 (+++) 26/53 (F)
OPN¼osteopontin.
aOsteopontin and CD44v6 expression were assessed by
immunohistochemistry and scored respectively as follows: +¼o10% positive cells;
++¼10–50% positive cells; and +++¼50–100% positive cells; L¼lower;
M¼lower and middle; and F¼full-thickness involvement of the epithelial layers.
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ssurvival curves reported in Figure 3A, the 8-years disease-free
survival was 94 and 91% for OPN (þ)- and OPN (þþ)-positive
cases, respectively, and 33% for OPN (þþþ)-positive cases
(two-sided log-rank test, Po0.0001; Figure 4A). Relative to
CD44v6 expression, the probability of recurrence was 94 and
75% for cases that showed basal (L), or basal and middle (M)
staining, respectively, and 38% for patient that had full-thickness
(F) positivity (two-sided log-rank test, P¼0.007; Figure 4B).
At the Pearson’s test, the frequency distribution of OPN and
CD44v6 expression levels were significantly correlated with relapse
(Table 4B).
Moreover, the correlation between OPN and CD44v6 expression
in patients with absence of relapse, with recurrence of dysplasia, or
with progression to LSCC resulted very significant at the Spear-
man’s rank correlation test (Table 3B). Finally, the contingency
analysis showed that the frequency distribution of OPN by CD44v6
were highly significant in combined or grouped types of relapse
(Table 4C).
DISCUSSION
An in-depth understanding of the factors involved in the initial
steps of LSCC development will facilitate the prevention and
diagnosis of this condition. Currently, histological grading and the
AB
CD
Figure 2 (A and C) A representative case of mild degree dysplasia showing weak immunostaining for OPN (A) and CD44v6 positivity restricted to the
lower third of the epithelium (C)( 150). (B and D) The same samples as in (A) negative for OPN immunostaining after incubation with isotype control
antiserum (B)(  150), and the same sample as in (C) negative for CD44v6 immunostaining after incubation with isotype control antiserum (D)(  150).
Table 3A Correlation of osteopontin and CD44v6 expression in all
laryngeal intraepithelial neoplasia (LIN) patients combined or grouped by
degree of dysplasia
LIN rs Ps
Combined (82) 0.8231 o0.0001
Mild (21) 0.9941 o0.0001
Moderate (8) 0.2622 ¼0.5304
Severe (53) 0.7957 o0.0001
Note: Correlation between osteopontin and CD44v6 expression in LIN patients
analysed by Spearman’s rank correlation test. Correlation coefficient (rs) and Ps are
shown (Pso0.05 was considered significant).
Table 3B Correlation of osteopontin and CD44v6 expression in all
laryngeal intraepithelial neoplasia (LIN) patients combined or grouped by
relapse
Relapse rs Ps
Combined (82) 0.8231 o0.0001
no (35) 0.8133 o0.0001
LIN (10) 0.5976 ¼0.0734
SCC (37)  0.7892 o0.0001
SCC¼squamous cell carcinoma. Note: Absence of relapse (no), recurrence of
dysplasia (LIN), progression to carcinoma (SCC). Correlation between osteopontin
and CD44v6 expression in LIN patients analysed by Spearman’s rank correlation test.
Correlation coefficient (rs) and Ps are shown (Pso0.05 was considered significant).
Table 4 Pearson’s test
v
2 P
A. Contingency analysis of osteopontin (OPN) and CD44v6 positivity by degree of
dysplasia
OPN 13.425 0.0094
CD44v6 16.198 0.0028
B. Contingency analysis of OPN and CD44v6 positivity by relapse (no, LIN, SCC)
OPN 21.780 o0.0002
CD44v6 9.567 0.0484
C. Contingency analysis of OPN positivity by CD44v6 expression in all laryngeal
intraepithelial neoplasia combined or grouped by relapse
Combined (82) 73.026 o0.0001
No (35) 32.694 o0.0001
LIN (10) 10.000 0.0067
SCC (37) 34.857 o0.0001
LIN¼laryngeal intraepithelial neoplasia; SCC¼squamous cell carcinoma. Note:
Absence of relapse (no), recurrence of dysplasia (LIN), and progression to carcinoma
(SCC).
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stopographical extension of laryngeal dysplasia are used to predict
the risk for cancer and to determine the treatment strategy (Rosai
et al, 1992; Zuckerberg, 2002; Johnson, 2003). Although significant
efforts have been made to identify molecular markers of the
clinical outcome of premalignant laryngeal lesion, still neither
single nor combination of markers is accepted in clinical practice
(Tabor et al, 2002).
We have previously reported that both OPN and CD44v6 are
highly expressed in invasive LSCC (Celetti et al, 2005). Here, we
have explored whether the same ligand/receptor pair is involved in
the premalignant phases as well. To this aim, we have investigated
OPN and CD44v6 in a set of laryngeal dysplasia samples and
correlated their expression level to histological grading and clinical
outcome. Both OPN and CD44v6 were consistently overexpressed
in dysplastic but not hyperplastic or metaplastic mucosa.
Dysplasia, in particular high-grade dysplasia, is regarded as a
preneoplastic condition (Rosai et al, 1992). Importantly, OPN/
CD44v6 overexpression was significantly correlated with the
degree of dysplasia, type of recurrence, and reduced disease-free
survival. Taken together, these findings suggest that OPN
signalling through CD44v6 may play a role in the establishment
of dyplastic changes in the laryngeal epithelium. Interestingly, it
has been recently reported that genetic deletion of OPN in
transgenic mice did not change the rate of hyperplasia formation
but caused a reduction of benign papilloma formation after the
two-stage skin chemical carcinogenesis protocol; thus, also in this
experimental model system, OPN is involved in the early phases of
tumorigenesis (Hsieh et al, 2006).
Osteopontin is able to engage several cell surface receptors,
including integrins and CD44 variants. In particular, OPN binds
CD44 proteins that contain v6-encoded sequences, and OPN/
CD44v6 binding has been implicated in carcinogenesis (Ponta
et al, 2003). Here, we show that OPN expression levels were
paralleled by intense expression of CD44v6; at contingency
analysis, the frequency distribution of OPN expression by
CD44v6 positivity resulted highly significant at Pearson’s test;
moreover, the association between OPN and CD44v6 immunor-
eactivity was highly significant at the Spearman’s correlation
coefficient test, suggesting that CD44v6 is at least one of the
functional OPN receptors in laryngeal dysplasia.
To investigate whether the OPN/CD44v6 overexpression was
causally related with dysplasia, cytological changes induced by
OPN stimulation of primary human keratinocytes, obstructed by
CD44 blockade, have been observed (Celetti A et al, in prepara-
tion). Addressing CD44 as a functional receptor for OPN would be
important to explore the molecular mechanism underlying
dysplastic changes induced by the OPN/CD44 axis. It is known
that CD44 triggering stimulates diverse signalling pathways,
including activation of ERK (Bourguignon et al, 2005), RAC
(Teramoto et al, 2005), and RHO (Bourguignon et al, 2003), as well
as secretion of soluble factors, like cytokines and metalloprotei-
nases (Zhang et al, 2002; Bourguignon et al, 2003; Murphy et al,
2005). These pathways are potentially involved in dysplastic
changes induced by OPN/CD44v6.
A model for the initiation and progression of colorectal cancer
has become a paradigm for other human solid tumours (Fearon
and Vogelstein, 1990). Like colorectal cancer, HNSCC is thought to
OPN CD44v6
AB
C D
Figure 3 (A and B) An area of incomplete squamous metaplasia,
negative for OPN (A), and CD44v6 (B) immunostaining ( 250).
(C and D) Another case of incomplete squamous metaplasia (patient
with a history of laryngeal SCC), showing an intense OPN (C) and CD44v6
(D) immunostaining ( 106).
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Figure 4 Osteopontin and CD44v6 staining in laryngeal dysplasia
negatively correlates with disease-free survival. Kaplan–Meier survival
plots for patients grouped on the basis of the OPN (A) or CD44v6
(B) expression level. (A) Patients were stratified into three categories
(þ (n¼21), þþ (n¼5), and þþþ (n¼25)) based on OPN
immunostaining intensity. (B) Patients were stratified into three categories
(L (n¼18), M (n¼10), and F (n¼23) based on the thickness of CD44v6
staining). The P-value was determined by a two-sided log-rank test.
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sprogress through a series of well-defined clinical and histopatho-
logical stages. While not all of the specific mutations required for
progression have been delineated, a working molecular model has
been proposed (Silverman, 2003). The loss of chromosomal
regions 3p and 9p21 are among the first identified genetic changes
(Mao et al, 1996; Sanz-Ortega et al, 2003). In particular, loss-
of-heterozygosity (LOH) at 9p21 in conjunction with promoter
hypermethylation results is the inactivation of the CDKN2A gene,
coding for the cyclin-dependent kinase inhibitor 2A (p16INK4).
This alteration occurs prior to the development of histologic atypia
and is associated with the transition from normal to hyperplastic/
metaplastic mucosa (Papadimitrakopoulou et al, 2001; Sanz-
Ortega et al, 2003). Subsequent LOH at 17p with mutation of the
TP53 tumour suppressor gene is associated with progression to
dysplasia (Boyle et al, 1993). The overexpression of the EGF
receptor is also an early event in carcinogenesis (Rubin Grandis
et al, 1998). Amplification and overexpression of the CCND1 gene,
encoding cyclin D1 is a common late event in HNSCC formation
(Michalides et al, 1995; Izzo et al, 1998; Chatrath et al, 2006). Our
findings suggest that the upregulation of the OPN/CD44v6 axis is
an additional early event during the progression of laryngeal
dysplasia. Thus, early immunocytochemical detection of OPN and
CD44v6 can be exploited to set a screening test for laryngeal
dysplasia. Moreover, perturbation of OPN/CD44v6 signalling may
represent a promising novel strategy to prevent progression of
laryngeal preneoplastic lesions.
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